Comparison of the pharmacokinetics of nicotine following single and ad libitum use of a tobacco heating system or combustible cigarettes

Nicotine and Tobacco Research

Volumn 18, Issue 5, 2016, Pages 557-563

  Picavet, Patrick ^a   Haziza, Christelle ^a   Lama, Nicola ^a   Weitkunat, Rolf ^a   Lüdicke, Frank ^a  

^a Philip Morris Products SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINE;

ABDOMINAL PAIN; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BEHAVIOR ASSESSMENT; BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; COUGH FREQUENCY; COUGH INTENSITY; COUGHING; CROSSOVER PROCEDURE; DEVICE SAFETY; DIZZINESS; ELECTRONIC CIGARETTE; FEMALE; HEADACHE; HUMAN; LIKERT SCALE; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PRESYNCOPE; PRIORITY JOURNAL; QUESTIONNAIRE OF SMOKING URGES; RANDOMIZED CONTROLLED TRIAL; REWARD; SATISFACTION; SPUTUM ANALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TOBACCO HEATING SYSTEM; TOBACCO USE; UNITED KINGDOM; WITHDRAWAL SYNDROME; BLOOD; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGY; SMOKING; TOBACCO; YOUNG ADULT;

ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINE; SMOKING; TOBACCO PRODUCTS; YOUNG ADULT;

EID: 84964940761     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntv220     Document Type: Article

References (28)

1. Stratton K, Shetty P, Wallace R, Bondurant S. Clearing the smoke: assessing the science base for tobacco harm reduction. Tob Control. 2001;10(2):189-195. doi:10.1136/tc.10.2.189.
2. Breland AB, Buchhalter AR, Evans SE, Eissenberg T. Evaluating acute effects of potential reduced-exposure products for smokers: clinical laboratory methodology. Nicotine Tob Res. 2002;4(suppl 2):S131-140. doi:10.1080/1462220021000032780.
3. Bullen C, McRobbie H, Thornley S, Glover M, Lin R, Laugesen M. Effect of an electronic nicotine delivery device (e cigarette) on desire to smoke and withdrawal, user preferences and nicotine delivery: randomised crossover trial. Tob Control. 2010;19(2):98-103. doi:10.1136/tc.2009.031567.
4. Breland AB, Kleykamp BA, Eissenberg T. Clinical laboratory evaluation of potential reduced exposure products for smokers. Nicotine Tob Res. 2006;8(6):727-738.
5. Orr MS. Electronic cigarettes in the USA: a summary of available toxicology data and suggestions for the future. Tob Control. 2014;23(suppl 2): ii18-22. doi:10.1136/tobaccocontrol-2013-051474.
6. Hatsukami DK, Biener L, Leischow SJ, Zeller MR. Tobacco and nicotine product testing. Nicotine Tob Res. 2012;14(1):7-17. doi:10.1093/ntr/ ntr027.
7. Le Houezec J, McNeill A, Britton J. Tobacco, nicotine and harm reduction. Drug Alcohol Rev. 2011;30(2):119-123. doi:10.1111/j.1465-3362.2010.00264.x.
8. Slade J, Connolly GN, Lymperis D. Eclipse: does it live up to its health claims? Tob Control. 2002;11(suppl 2):ii64-70. doi:10.1136/tc.11. suppl_2.ii64.
9. Wonnacott S, Russell MAH, Stolerman IP. Nicotine Psychopharmacology: Molecular, Cellular, and Behavioural Aspects. Oxford, United Kingdom: Oxford University Press; 1990.
10. Lee EM, Malson JL, Moolchan ET, Pickworth WB. Quantitative comparisons between a nicotine delivery device (Eclipse) and conventional cigarette smoking. Nicotine Tob Res. 2004;6(1):95-102. doi:10.1080/146222 00310001656911.
11. Breland AB, Acosta MC, Eissenberg T. Tobacco specific nitrosamines and potential reduced exposure products for smokers: a preliminary evaluation of Advance. Tob Control. 2003;12(3):317-321. doi:10.1136/tc.12.3.317.
12. Eissenberg T. Electronic nicotine delivery devices: ineffective nicotine delivery and craving suppression after acute administration. Tob Control. 2010;19(1):87-88. doi:10.1136/tc.2009.033498.
13. Zenzen V, Diekmann J, Gerstenberg B, Weber S, Wittke S, Schorp MK. Reduced exposure evaluation of an Electrically Heated Cigarette Smoking System. Part 2: smoke chemistry and in vitro toxicological evaluation using smoking regimens reflecting human puffing behavior. Regul Toxicol Pharmacol. 2012;64(2) (suppl):S11-S34. doi:10.1016/j. yrtph.2012.08.004.
14. Picavet P, Haziza C, De La Bourdonnaye G, et al. Reduced exposure to harmful and potentially harmful smoke constituents after five days of use of a candidate modified risk tobacco product: the Tobacco Heating System 2.1. Presentation at the 20th Annual Meeting of the Society for Research on Nicotine and Tobacco; February 5-8, 2014; Seattle, WA. Abstract PA-10-2. www.srnt.org/ conferences/2014/pdf/SRNT_2014_Abstracts_F.pdf. Accessed December 12, 2014.
15. Gourlay SG, Benowitz NL. Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine. Clin Pharmacol Ther. 1997;62(4):453-463. doi:10.1016/S0009-9236(97)90124-7.
16. Fagerstrom K, Russ C, Yu CR, Yunis C, Foulds J. The Fagerstrom Test for Nicotine Dependence as a predictor of smoking abstinence: a pooled analysis of varenicline clinical trial data. Nicotine Tob Res. 2012;14(12):1467-1473, doi 10.1093/ntr/nts018.
17. Jacob P III, Yu L, Duan M, Ramos L, Yturralde O, Benowitz NL. Determination of the nicotine metabolites cotinine and trans-3'-hydroxycotinine in biologic fluids of smokers and non-smokers using liquid chromatography-tandem mass spectrometry: biomarkers for tobacco smoke exposure and for phenotyping cytochrome P450 2A6 activity. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879(3-4):267-276. doi:10.1016/j. jchromb.2010.12.012.
18. Cox LS, Tiffany ST, Christen AG. Evaluation of the brief questionnaire of smoking urges (QSU-Brief) in laboratory and clinical settings. Nicotine Tob Res. 2001;3(1):7-16. doi:10.1080/14622200124218.
19. Cappelleri JC, Bushmakin AG, Baker CL, Merikle E, Olufade AO, Gilbert DG. Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire. Addict Behav. 2007;32(5):912-923.
20. Lingling H. Calculating the point estimate and confidence interval of Hodges-Lehmann's median using SAS® software. Presentation at the Annual Meeting of the SouthEast SAS®Users Group; October 19-22, 2008; Birmingham, AL. Paper (ST-154). http://analytics.ncsu.edu/ sesug/2008/ST-154.pdf. Accessed July 10, 2014.
21. Scherer G. Smoking behaviour and compensation: a review of the literature. Psychopharmacology (Berl). 1999;145(1):1-20. doi:10.1007/ s002130051027.
22. Benowitz NL, Hukkanen J, Jacob P III. Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacol. 2009;(192):29-60. doi:10.1007/978-3-540-69248-5_2.
23. Digard H, Proctor C, Kulasekaran A, Malmqvist U, Richter A. Determination of nicotine absorption from multiple tobacco products and nicotine gum. Nicotine Tob Res. 2013;15(1):255-261. doi:10.1093/ntr/nts123.
24. Yuki D, Kikuchi A, Miura N, Kakehi A, Onozawa M. Good relationship between saliva cotinine kinetics and plasma cotinine kinetics after smoking one cigarette. Regul Toxicol Pharmacol. 2013;67(2):240-245. doi:10.1016/j.yrtph.2013.08.002.
25. Teneggi V, Squassante L, Iavarone L, Milleri S, Bye A, Gomeni R. Correlation and predictive performances of saliva and plasma nicotine concentration on tobacco withdrawal-induced craving. Br J Clin Pharmacol. 2002;54(4):407-414. doi:10.1046/j.0306-5251.2002.01650.x.
26. Cobb CO, Weaver MF, Eissenberg T. Evaluating the acute effects of oral, non-combustible potential reduced exposure products marketed to smokers. Tob Control. 2010;19(5):367-373. doi:10.1136/tc.2008.028993.
27. Hanson K, O'Connor R, Hatsukami D. Measures for assessing subjective effects of potential reduced-exposure products. Cancer Epidemiol Biomarkers Prev. 2009;18(12):3209-3224. doi:10.1158/1055-9965.EPI-09-0971.
28. Trtchounian A, Williams M, Talbot P. Conventional and electronic cigarettes (e-cigarettes) have different smoking characteristics. Nicotine Tob Res. 2010;12(9):905-912. doi:10.1093/ntr/ntq114.